No Data
North China Pharmaceutical Company.Ltd's (SHSE:600812) Shares Lagging The Industry But So Is The Business
We Think That There Are Some Issues For North China Pharmaceutical Company.Ltd (SHSE:600812) Beyond Its Promising Earnings
North China Pharmaceutical (600812.SH): Subsidiary company received government subsidies
On October 30, GeLongHui announced that North China Pharmaceutical (600812.SH) disclosed that its subsidiary received a total of RMB 1.5584 million in government subsidies related to income from July 24, 2024 to the date of this announcement, accounting for 31.87% of the net income attributable to the shareholders of the listed company in 2023.
Third Quarter Report 2024
Is North China Pharmaceutical Company.Ltd (SHSE:600812) A Risky Investment?
North China Pharmaceutical (600812.SH): Entecavir Propofol Tenofovir Tablets (II) obtained the "Pharmaceutical Registration Certificate".
On September 27, the North China Pharmaceutical (600812.SH) announced that its subsidiary, North China Pharmaceutical Huakun Hebei Biotechnology Co., Ltd. (referred to as 'Huakun Company'), received the 'Drug Registration Certificate' approved and issued by the National Medical Products Administration for Enquatam Bifenofeine Tenofovir Tablet (II) (200mg/25mg). Enquatam Bifenofeine Tenofovir Tablet (II) is used in combination with other antiretroviral drugs to treat human immunodeficiency virus Type 1 (HIV-1) infection in adults and adolescents (aged 12 and older with a body weight of at least 35kg). It is also suitable for
North China Pharmaceutical Company.Ltd (SHSE:600812) Not Doing Enough For Some Investors As Its Shares Slump 28%
